Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (MX:BMY) — Drug Manufacturers - General. Broj burzi na kojima se trguje dionicama tvrtke: 6. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.
O Tvrtki
- Web-Stranica
- bms.com
- Odnosi s Investitorima
- bms.com/investors.html
- Sektor
- Healthcare · Drug Manufacturers - General
- Sjedište
- PRINCETON, United States
- Glavni Direktor
- Christopher S. Boerner
- Zaposlenici
- 32 500
- Osnovana
- 1989
- Na Burzi od
- 01.03.2005 (MX:BMY)
- Dionice u Optjecaju
- 2.04 mlrd. na dan 2026-07-22
- Slobodno Prenosive Dionice
- 2.04 mlrd.
- Tržišna Kapitalizacija
- 128.41 mlrd. USD
- Insajderi
- 0.1%
- Institucionalni Ulagači
- 84.87%
- Djelatnost (SIC)
- Pharmaceutical Preparations
- Pravni Oblik
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- Omjer Isplate
- 54.9%
- FCF
- 11.4 mlrd. USD45%
- Dug
- 43.9 mlrd. USD3.1 g. FCF
- Dividendni Staž
- 54 g.
- Zarada, FCF i isplaćene dividende — za 12 mjeseci do 30.06.2026 (najnovije izvješće tvrtke).
Opis
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Burze i Oznake
| Burza | Oznaka | Valuta | Cijena | Vrsta |
|---|---|---|---|---|
| US USA Stocks | BMY glavna | USD | 59.12 -0.77% | obične dionice |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | obične dionice |
| MI Borsa Italiana (Milan) | 1BMY dodatna | EUR | 53.13 +0.28% | obične dionice |
| MX Mexican Stock Exchange | BMY dodatna | MXN | 1 047 -3.81% | obične dionice |
| VI Vienna Stock Exchange | BMYS dodatna | EUR | 52.98 +0.34% | obične dionice |
| XETRA Xetra | BRM dodatna | EUR | 53.04 +0.89% | obične dionice |
Dividende
Bristol-Myers Squibb Company (BMY) isplaćuje dividende kvartalno. Godišnje (12 mjeseci do uključivo posljednje najavljene isplate): 45.2778 MXN po dionici (isplata: 4). To je otprilike 4.32% trenutne cijene dionice. Prema povijesti isplata, sljedeći datum ex-dividende očekuje se oko 04.01.2027. Godine neprekinutih dividendi: 54.
| Ex-Datum | Isplata | Iznos | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-10-02 | — | 11.3195 MXN | 1.1/4.3 % | tromjesečno | MX:BMY |
| 2026-07-02 | — | 11.3195 MXN | 1.1/4.3 % | tromjesečno | MX:BMY |
| 2026-04-06 | — | 11.3195 MXN | 1.1/4.3 % | tromjesečno | MX:BMY |
| 2026-01-02 | — | 11.3195 MXN | 1.1/4.3 % | tromjesečno | MX:BMY |
| 2025-10-03 | — | 11.1398 MXN | 1.1/4.3 % | tromjesečno | MX:BMY |
| 2025-07-03 | — | 11.1398 MXN | 1.1/4.2 % | tromjesečno | MX:BMY |
| 2025-04-04 | — | 11.1398 MXN | 1.1/4.2 % | tromjesečno | MX:BMY |
| 2025-01-03 | — | 11.1398 MXN | 1.1/4.2 % | tromjesečno | MX:BMY |
| 2024-10-04 | — | 10.7804 MXN | 1.0/4.1 % | tromjesečno | MX:BMY |
| 2024-07-05 | — | 10.7804 MXN | 1.0/4.1 % | tromjesečno | MX:BMY |
| 2024-04-04 | — | 10.7804 MXN | 1.0/4.0 % | tromjesečno | MX:BMY |
| 2024-01-04 | — | 10.7804 MXN | 1.0/4.0 % | tromjesečno | MX:BMY |
| 2023-10-05 | — | 10.2414 MXN | 1.0/3.9 % | tromjesečno | MX:BMY |
| 2023-07-06 | — | 10.2414 MXN | 1.0/3.9 % | tromjesečno | MX:BMY |
| 2023-04-10 | — | 10.2414 MXN | 1.0/3.8 % | tromjesečno | MX:BMY |
| 2023-01-05 | — | 10.2414 MXN | 1.0/3.8 % | tromjesečno | MX:BMY |
| 2022-10-06 | — | 9.7024 MXN | 0.9/3.7 % | tromjesečno | MX:BMY |
| 2022-06-30 | — | 9.7024 MXN | 0.9/2.8 % | tromjesečno | MX:BMY |
| 2022-03-31 | — | 9.7024 MXN | 0.9/1.9 % | tromjesečno | MX:BMY |
| 2022-01-06 | — | 9.7024 MXN | 0.9/0.9 % | tromjesečno | MX:BMY |
Vijesti Ovog Tjedna
Priopćenja za medije s web stranice za investitore tvrtke, ažurirana svakodnevno. Poveznice vode na web stranicu tvrtke. Naslovi su na izvornom jeziku, kao na web stranici tvrtke.
Najveći Imatelji
| Imatelj | Udio | Dionice | Datum Izvješća |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mil. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mil. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mil. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mil. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mil. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mil. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mil. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mil. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mil. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mil. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mil. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mil. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mil. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mil. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mil. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mil. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mil. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mil. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mil. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
Prijavite se s Google